account_circle

OFF-X NEWS

CLARIVATE ACQUIRES BIOINFOGATE, REINFORCING POSITION AS PREMIER PROVIDER OF END-TO-END RESEARCH INTELLIGENCE SOLUTIONS FOR LIFE SCIENCES

Expanding and integrating drug toxicity data and translational safety intelligence from OFF-X into all aspects of the life science cycle, allowing customers to make more informed decisions

Aug 04 ,2021


FDA AND BIOINFOGATE AGREE TO EXTEND FOR 2 ADDITIONAL YEARS THE MATERIAL TRANSFER AGREEMENT (MTA) TO PROVIDE AGENCY-WIDE ACCESS TO THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL
The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
EXTERNAL VALIDATION OF BIOINFOGATE’S OFF-X FAERS CURATION PROCESS & STATISTICAL SIGNAL EXTRACTION TO BE SUPPORTED BY INTAGE HEALTHCARE’S CZEEKV PRO
Bioinfogate has established an agreement with INTAGE Healthcare to perform an external validation of their methodologies to curate information from FAERS and extract safety signals using well-established statistical methods with the CzeekV Pro database system.
BIOINFOGATE’S OFF-X REACHES ONE MILLION SAFETY ALERTS
OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest.
NEW COLLABORATION BETWEEN BIOINFOGATE AND INTAGE HEALTHCARE TO DELIVER JAPANESE PHARMACOVIGILANCE INSIGHTS IN OFF-X
Bioinfogate will integrate JADER case reports and pharmacovigilance signals into OFF-X to complement its unique translational view of safety intelligence.
LAUNCH OF BIOINFOGATE’S OFF-X TRANSLATABILITY DASHBOARD
The Translatability Dashboard supports understanding of how toxicity events derived from experimental assays and animal models translate to the clinic
FDA AND BIOINFOGATE AGREE TO EXTEND THE MATERIAL TRANSFER AGREEMENT (MTA) TO PROVIDE AGENCY-WIDE ACCESS TO THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL
The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
BIOINFOGATE’S OFF-X PROVIDES A DEDICATED “COVID-19” SECTION
The COVID-19 section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care.
BIOINFOGATE’S OFF-X REACHES HALF MILLION SAFETY ALERTS
OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest.
BIOINFOGATE TO PRESENT AT THE CHEM-BIO INFORMATICS SOCIETY (CBI) ANNUAL MEETING (TOKYO, JAPAN, OCTOBER 22-24, 2019)
Bioinfogate has been invited to a speak at the Chem-Bio Informatics Society (CBI) Annual Meeting “”Towards Seamless Integration of Structural Biology and Information Science”~Dawn of the AI era in drug discovery~” which takes place in Tokyo, Oct. 22-24, 2019.
BIOINFOGATE EXHIBITING AT THE SAFETY PHARMACOLOGY SOCIETY ANNUAL MEETING IN BARCELONA
Bioinfogate will be showcasing some of their recent developments at the Safety Pharmacology Society Annual Meeting in Barcelona, September 23-26, 2019.
RESEARCH INSTITUTES OF SWEDEN (RISE) INITIATES SUBSCRIPTION TO BIOINFOGATE OFF-X
Bioinfogate announced today the signing of a licensing agreement with RISE to access Bioinfogate’s translational safety intelligence portal, OFF-X.
VHIO AND BIOINFOGATE PARTNER TO ENHANCE SAFETY ASSESSMENT
Announced today, the Vall d'Hebron Institute of Oncology - Bioinfogate collaboration will validate the utility of the OFF-X translational safety intelligence portal in the design of novel clinical trials, including first-in-human studies.
BIOINFOGATE EXHIBITING AT WORLD PHARMA WEEK IN BOSTON, MA (JUNE 17-20, 2019)
Bioinfogate will be showcasing some of their recent developments at World Pharma Week in Boston, MA, June 17-20 2019.
FDA AND BIOINFOGATE AGREE TO EXTEND THE MATERIAL TRANSFER AGREEMENT (MTA) TO ACCESS THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL
The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
NEW ALLIANCE BETWEEN CLARIVATE ANALYTICS AND BIOINFOGATE TO DELIVER SAFETY & TOXICITY INTELLIGENCE TO PHARMA AND HEALTHCARE RESEARCHERS AND DECISION MAKERS
Bioinfogate will cross-link the OFF-X translational safety intelligence portal with the Cortellis suite of solutions from Clarivate Analytics to enable enhanced insights for targets and drugs of interest